FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011393181> ?p ?o ?g. }

• W2011393181 endingPage "1183" @default.
• W2011393181 startingPage "1175" @default.
• W2011393181 abstract "To evaluate the long-term safety and efficacy of multiple intravitreal ranibizumab injections (Lucentis, Genentech, Inc., South San Francisco, CA) administered at the investigator's discretion in patients with choroidal neovascularization secondary to age-related macular degeneration.An open-label, multicenter, extension study.Patients who completed the controlled treatment phase of 1 of 3 prospective, randomized, 2-year clinical trials of ranibizumab were eligible for enrollment. Analyses were performed for 3 groups: (1) patients treated with ranibizumab in the initial study (ranibizumab treated-initial; n = 600); (2) patients randomized to control who crossed over to receive ranibizumab (ranibizumab treated-XO; n = 190); and (3) ranibizumab-naïve patients (ranibizumab untreated; n = 63).Ranibizumab 0.5 mg was administered at the investigator's discretion. Adverse events (AEs) and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) assessments were conducted at study visits every 3 to 6 months.Incidence and severity of AEs.There was 1 occurrence of mild endophthalmitis per 3552 HORIZON injections in the ranibizumab treated-initial/ranibizumab treated-XO groups. There were no serious AE reports of lens damage, retinal tears, or rhegmatogenous retinal detachments in the study eyes. The proportion of patients with any single postdose intraocular pressure ≥30 mmHg was 9.2%, 6.6%, and 0%, and the proportion of patients with glaucoma was 3.2%, 4.2%, and 3.2% in the ranibizumab treated-initial, ranibizumab treated-XO, and ranibizumab untreated groups, respectively. Cataract AEs were less frequent in the ranibizumab untreated group: 6.3% versus 12.5% and 12.1% in the ranibizumab treated-initial and ranibizumab treated-XO groups, respectively. The proportion of patients with arterial thromboembolic events as defined by the Antiplatelet Trialists' Collaboration was 5.3% in the ranibizumab treated-initial and ranibizumab treated-XO groups, and 3.2% in the ranibizumab untreated group. At month 48 (2 years of HORIZON), the mean change in BCVA (ETDRS letters) relative to the initial study baseline was 2.0 in the ranibizumab treated-initial group versus -11.8 in the pooled ranibizumab treated-XO and ranibizumab untreated groups.Multiple ranibizumab injections were well tolerated for ≥4 years. With less frequent follow-up leading to less treatment, there was an incremental decline of the visual acuity (VA) gains achieved with monthly treatment.Proprietary or commercial disclosure may be found after the references." @default.
• W2011393181 created "2016-06-24" @default.
• W2011393181 creator A5010803177 @default.
• W2011393181 creator A5015766632 @default.
• W2011393181 creator A5020628503 @default.
• W2011393181 creator A5027046934 @default.
• W2011393181 creator A5062954288 @default.
• W2011393181 creator A5082592591 @default.
• W2011393181 creator A5084185055 @default.
• W2011393181 date "2012-06-01" @default.
• W2011393181 modified "2023-09-25" @default.
• W2011393181 title "HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration" @default.
• W2011393181 cites W1481978003 @default.
• W2011393181 cites W1696340081 @default.
• W2011393181 cites W1987699263 @default.
• W2011393181 cites W2012906786 @default.
• W2011393181 cites W2068742492 @default.
• W2011393181 cites W2075984382 @default.
• W2011393181 cites W2085712747 @default.
• W2011393181 cites W2085752173 @default.
• W2011393181 cites W2091989599 @default.
• W2011393181 cites W2124415048 @default.
• W2011393181 cites W4239471829 @default.
• W2011393181 doi "https://doi.org/10.1016/j.ophtha.2011.12.016" @default.
• W2011393181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22306121" @default.
• W2011393181 hasPublicationYear "2012" @default.
• W2011393181 type Work @default.
• W2011393181 sameAs 2011393181 @default.
• W2011393181 citedByCount "310" @default.
• W2011393181 countsByYear W20113931812012 @default.
• W2011393181 countsByYear W20113931812013 @default.
• W2011393181 countsByYear W20113931812014 @default.
• W2011393181 countsByYear W20113931812015 @default.
• W2011393181 countsByYear W20113931812016 @default.
• W2011393181 countsByYear W20113931812017 @default.
• W2011393181 countsByYear W20113931812018 @default.
• W2011393181 countsByYear W20113931812019 @default.
• W2011393181 countsByYear W20113931812020 @default.
• W2011393181 countsByYear W20113931812021 @default.
• W2011393181 countsByYear W20113931812022 @default.
• W2011393181 countsByYear W20113931812023 @default.
• W2011393181 crossrefType "journal-article" @default.
• W2011393181 hasAuthorship W2011393181A5010803177 @default.
• W2011393181 hasAuthorship W2011393181A5015766632 @default.
• W2011393181 hasAuthorship W2011393181A5020628503 @default.
• W2011393181 hasAuthorship W2011393181A5027046934 @default.
• W2011393181 hasAuthorship W2011393181A5062954288 @default.
• W2011393181 hasAuthorship W2011393181A5082592591 @default.
• W2011393181 hasAuthorship W2011393181A5084185055 @default.
• W2011393181 hasConcept C118487528 @default.
• W2011393181 hasConcept C126322002 @default.
• W2011393181 hasConcept C141071460 @default.
• W2011393181 hasConcept C168563851 @default.
• W2011393181 hasConcept C197934379 @default.
• W2011393181 hasConcept C2776403814 @default.
• W2011393181 hasConcept C2776694085 @default.
• W2011393181 hasConcept C2777235844 @default.
• W2011393181 hasConcept C2777802072 @default.
• W2011393181 hasConcept C2778257484 @default.
• W2011393181 hasConcept C2781100027 @default.
• W2011393181 hasConcept C2781359195 @default.
• W2011393181 hasConcept C71924100 @default.
• W2011393181 hasConceptScore W2011393181C118487528 @default.
• W2011393181 hasConceptScore W2011393181C126322002 @default.
• W2011393181 hasConceptScore W2011393181C141071460 @default.
• W2011393181 hasConceptScore W2011393181C168563851 @default.
• W2011393181 hasConceptScore W2011393181C197934379 @default.
• W2011393181 hasConceptScore W2011393181C2776403814 @default.
• W2011393181 hasConceptScore W2011393181C2776694085 @default.
• W2011393181 hasConceptScore W2011393181C2777235844 @default.
• W2011393181 hasConceptScore W2011393181C2777802072 @default.
• W2011393181 hasConceptScore W2011393181C2778257484 @default.
• W2011393181 hasConceptScore W2011393181C2781100027 @default.
• W2011393181 hasConceptScore W2011393181C2781359195 @default.
• W2011393181 hasConceptScore W2011393181C71924100 @default.
• W2011393181 hasIssue "6" @default.
• W2011393181 hasLocation W20113931811 @default.
• W2011393181 hasLocation W20113931812 @default.
• W2011393181 hasOpenAccess W2011393181 @default.
• W2011393181 hasPrimaryLocation W20113931811 @default.
• W2011393181 hasRelatedWork W1995044506 @default.
• W2011393181 hasRelatedWork W2042956061 @default.
• W2011393181 hasRelatedWork W2049577742 @default.
• W2011393181 hasRelatedWork W2054981704 @default.
• W2011393181 hasRelatedWork W2068871928 @default.
• W2011393181 hasRelatedWork W2227583243 @default.
• W2011393181 hasRelatedWork W2314067402 @default.
• W2011393181 hasRelatedWork W2396116581 @default.
• W2011393181 hasRelatedWork W2769959318 @default.
• W2011393181 hasRelatedWork W2599281049 @default.
• W2011393181 hasVolume "119" @default.
• W2011393181 isParatext "false" @default.
• W2011393181 isRetracted "false" @default.
• W2011393181 magId "2011393181" @default.
• W2011393181 workType "article" @default.